middle.news

Microba Accelerates Growth with Record Q4 Sales and Eyes FY26 Break-Even

9:06am on Tuesday 22nd of July, 2025 AEST Healthcare
Read Story

Microba Accelerates Growth with Record Q4 Sales and Eyes FY26 Break-Even

9:06am on Tuesday 22nd of July, 2025 AEST
Key Points
  • Q4 FY25 MetaXplore test sales up 88% in Australia and 74% quarter-on-quarter in the UK
  • FY25 revenue reaches $15.67 million, a 30% increase year-on-year
  • Strategic shift away from legacy products towards core diagnostics and partnering for therapeutics
  • Promising clinical study results support diagnostic tests’ impact on gastrointestinal disease management
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Microba Life Sciences (ASX:MAP)
OPEN ARTICLE